培美曲塞联合顺铂对晚期非小细胞肺癌的化疗效果和血清肿瘤标志物的影响

Effects of Pemetrexed Combined with Cisplatin on Chemotherapy and Serum Tumor Markers in Advanced Non-small Cell Lung Cancer

目的探讨对晚期非小细胞肺癌患者采用培美曲塞联合顺铂化疗的临床效果及对血清肿瘤标志物的影响。方法选取该院2020年1—12月收治晚期非小细胞肺癌患者80例,按照随机数表法分为两组,对照组(n=40)采用多西他赛联合顺铂治疗,观察组(n=40)采用培美曲塞联合顺铂治疗,比较两组临床疗效,检测治疗前后两组血清癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角质素片段抗原21-1(CYFRA21-1)、糖类抗原125(CA-125)水平,统计两组不良反应发生率进行比较。结果观察组治疗总有效率62.50%高于对照组40.00%,差异有统计学意义(χ^(2)=4.053,P<0.05)。治疗后,观察组CEA、NSE、CYFRA21-1、CA-125水平分别为(6.17±0.84)ng/mL、(15.64±3.23)ng/mL、(9.51±2.32)ng/mL、(75.43±13.04)U/mL,均小于对照组,差异有统计学意义(t=9.825、4.626、5.437、5.642,P<0.05)。对照组皮肤反应、骨髓抑制、消化道反应发生率分别为17.50%、12.50%、12.50%,与观察组15.00%、10.00%、20.00%比较,差异无统计学意义(χ^(2)=0.092、0.000、0.827,P>0.05)。结论对晚期非小细胞肺癌患者采用培美曲塞联合顺铂治疗效果理想,能够有效改善血清肿瘤标志物水平,且不会导致患者不良反应的明显增加,用药安全可靠。

Objective To investigate the clinical effect of pemetrexed combined with cisplatin chemotherapy in patients with advanced non-small cell lung cancer and its influence on serum tumor markers.Methods Selected in the hospital from January to December 2020 to treat 80 patients with advanced non-small cell lung cancer.They were divided into two groups according to the random number table method.The control group(n=40)was treated with docetaxel combined with cisplatin,and the observation group(n=40),pemetrexed combined with cisplatin was used to compare the clinical efficacy of the two groups.Serum carcinoembryonic antigen(CEA),neuron-specific enolase(NSE)and cytokeratin fragment antigen were detected before and after treatment.The levels of 21-1(CYFRA21-1)and carbohydrate antigen 125(CA-125),the incidence of adverse reactions between the two groups were counted for comparison.Results The total effective rate of treatment in the observation group was 62.50%,which was higher than 40.00%in the control group.The difference was statistically significant(χ^(2)=4.053,P<0.05).After treatment,the levels of CEA,NSE,CYFRA21-1,and CA-125 in the observation group were(6.17±0.84)ng/mL,(15.64±3.23)ng/mL,(9.51±2.32)ng/mL,(75.43±13.04)U/mL,all were smaller than the control group,the difference was statistically significant(t=9.825,4.626,5.437,5.642,P<0.05).The incidence of skin reaction,bone marrow suppression,and gastrointestinal reaction in the control group were 17.50%,12.50%,and 12.50%,respectively.There was no statistically significant difference compared with the observation group at 15.00%,10.00%,and 20.00%(χ^(2)=0.092,0.000,0.827,P>0.05).Conclusion Pemetrexed combined with cisplatin is an ideal treatment for patients with advanced non-small cell lung cancer.It can effectively improve the level of serum tumor markers without causing a significant increase in adverse reactions in patients.The medication is safe and reliable.